GLUT1 enhances mTOR activity independently of TSC2 and AMPK

American Journal of Physiology - Renal Physiology

Volumn 301, Issue 3, 2011, Pages

  Buller, Carolyn L ^a   Heilig, Charles W ^b   Brosius III, Frank C ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Diabetes; Mesangial cells; MTORC1

Indexed keywords

ADENYLATE KINASE; GLUCOSE; GLUCOSE TRANSPORTER 1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; RHEB PROTEIN; S6 KINASE; TUBERIN;

ANIMAL EXPERIMENT; ARTICLE; CELL LINE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; GLOMERULUS; HUMAN; HUMAN CELL; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE;

EID: 80052419165     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00472.2010     Document Type: Article

References (43)

1. Breyer MD, Bottinger E, Brosius FC, Coffman TM, Harris RC, Heilig CW, Sharma K. Mouse models of diabetic nephropathy. J Am Soc Nephrol 16: 27-45, 2005.
2. Brosius FC, Heilig CW. Glucose transporters in diabetic nephropathy. Pediatr Nephrol 20: 447-451, 2005.
3. Buller CL, Loberg RD, Fan MH, Zhu Q, Park JL, Vesely E, Inoki K, Guan KL, Brosius FC. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Am J Physiol Cell Physiol 295: C836-C843, 2008.
4. Chen S, Heilig KO, Brosius FC, Heilig C. Diabetes increases glomerular GLUT1 and antisense-GLUT1 protects against diabetic glomerulosclerosis (Abstract). J Am Soc Nephrol 14: 46A, 2003.
5. D'Agord Schaan B, Lacchini S, Bertoluci M, Irigoyen M, Machado U, Schmid H. Increased renal GLUT1 abundance and urinary TGF-beta 1 in streptozotocin-induced diabetic rats: implications for the development of nephropathy complicating diabetes. Horm Metab Res 33: 664-669, 2001.
6. Gnudi L, Thomas SM, Viberti G. Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism. J Am Soc Nephrol 18: 2226-2232, 2007.
7. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-226, 2008.
8. Harris TE, Lawrence JC. TOR signaling. Sci STKE 212: 1-17, 2003.
9. Heilig CW, Brosius FC, Cunningham C. Role for GLUT1 in diabetic glomerulosclerosis. Expert Rev Mol Med 8: 1-18, 2006.
10. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 96: 1802-1814, 1995.
11. Heilig CW, Kreisberg JI, Freytag S, Murakami T, Ebina Y, Guo L, Heilig K, Loberg RD, Qu X, Jin Y, Henry D, Brosius FC. Antisense GLUT-1 protects mesangial cells from induction of GLUT-1 and fibronectin expression. Am J Physiol Renal Physiol 280: F657-F666, 2001.
12. Heilig CW, Liu Y, England RL, Freytag SO, Gilbert JD, Heilig KO, Zhu M, Concepcion LA, Brosius FC. D-Glucose stimulates mesangial cell GLUT1 expression and basal IGF-I-sensitive glucose uptake in rat mesangial cells: implications for diabetic nephropathy. Diabetes 46: 1030-1039, 1997.
13. Heilig CW, Saunders T, Brosius FC, Moley K, Heilig K, Baggs R, Guo L, Conner D. Glucose transporter-1-deficient mice exhibit impaired development and deformities that are similar to diabetic embryopathy. Proc Natl Acad Sci USA 100: 15613-15618, 2003.
14. Hino O, Klein-Szanto AJ, Freed JJ, Testa JR, Brown DQ, Vilensky M, Yeung RS, Tartof KD, Knudson AG. Spontaneous and radiation-induced renal tumors in the Eker rat model of dominantly inherited cancer. Proc Natl Acad Sci USA 90: 327-331, 1993.
15. Inoki K, Guan KL. Complexity of the TOR signaling network. Trends Cell Biol 16: 206-212, 2006.
16. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17: 1829-1834, 2003.
17. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol 4: 648-657, 2002.
18. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590, 2003.
19. Kikkawa R, Koya D, Haneda M. Progression of diabetic nephropathy. Am J Kidney Dis 41: S19-S21, 2003.
20. Kim IH, Lee MN, Ryu SH, Park JW. Nanoscale mapping and affinity constant measurement of signal-transducing proteins by atomic force microscopy. Analytical Chemistry In press.
21. Kobayashi T, Hirayama Y, Kobayashi E, Kubo Y, Hino O. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat Genet 9: 70-74, 1995.
22. Lee MN, Ha SH, Kim J, Koh A, Lee CS, Kim JH, Jeon H, Kim DH, Suh PG, Ryu SH. Glycolytic flux signals to mTOR through glyceraldehyde- 3-phosphate dehydrogenase-mediated regulation of Rheb. Mol Cell Biol 29: 3991-4001, 2009.
23. Li Y, Corradetti MN, Inoki K, Guan KL. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem Sci 29: 32-38, 2004.
24. Linden KC, DeHaan CL, Zhang Y, Glowacka S, Cox AJ, Kelly DJ, Rogers S. Renal expression and localization of the facilitative glucosetransporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy. Am J Physiol Renal Physiol 290: F205-F213, 2006.
25. Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, Rama I, Vidal A, Grinyo JM. Mammalian target of rapamycin pathway blockcade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 17: 1395-1404, 2006.
26. Loberg RD, Vesely E, Brosius FC. Enhanced glycogen synthase kinase-3 beta activity mediates hypoxia-induced apoptosis of vascular smooth muscle cells and is prevented by glucose transport and metabolism. J Biol Chem 277: 41667-41673, 2002.
27. Malhotra R, Brosius FC. Glucose uptake and glycolysis reduce hypoxiainduced apoptosis in cultured neonatal rat cardiac myocytes. J Biol Chem 274: 12567-12575, 1999.
28. Malhotra R, Tyson DG, Sone H, Aoki K, Kumagai AK, Brosius FC. Glucose uptake and adenoviral mediated GLUT1 infection decrease hypoxia-induced HIF-1a levels in cardiac myocytes. J Mol Cell Cardiol 34: 1063-1073, 2002.
29. Martin DE, Hall MN. The expanding TOR signaling network. Curr Opin Cell Biol 17: 158-166, 2005.
30. Mogyorosi A, Ziyadeh FN. GLUT1 and TGF-B: the link between hyperglycaemia and diabetic nephropathy. Nephrol Dial Transplant 14: 2827-2829, 1999.
31. Nagai K, Matsubara T, Mima A, Sumi E, Kanamori H, Iehara N, Fukatsu A, Yanagita M, Nakano T, Ishimoto Y, Kita T, Doi T, Arai H. Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int 68: 552-561, 2005.
32. NIDDK. US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010.
33. Pfafflin A, Brodbeck K, Heilig CW, Haring HU, Schleicher ED, Weigert C. Increased glucose uptake and metabolism in mesangial cells overexpressing glucose transporter 1 increases interleukin-6 and vascular endothelial growth factor production: role of AP-1 and HIF-1alpha. Cell Physiol Biochem 18: 199-210, 2006.
34. Ricci C, Iacobini C, Oddi G, Amadio L, Menini S, Rastaldi MP, Frasheri A, Pricci F, Pugliese F, Pugliese G. Role of TGF-beta/GLUT1 axis in susceptibility vs resistance to diabetic glomerulopathy in the Milan rat model. Nephrol Dial Transplant 21: 1514-1524, 2006.
35. Sakaguchi M, Isono M, Isshiki K, Sugimoto T, Koya D, Kashiwagi A. Inihibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun 340: 296-301, 2006.
36. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101, 2005.
37. Vesely ED, Heilig CW, Brosius FC. GLUT1-induced cFLIP expression promotes proliferation and prevents apoptosis in vascular smooth muscle cells. Am J Physiol Cell Physiol 297: C759-C765, 2009.
38. Wang Y, Heilig KO, Saunders T, Minto AW, Deb DK, Chang A, Brosius FC, Monteiro C, Heilig CW. Transgenic overexpression of GLUT1 in mouse glomeruli produces renal disease resembling diabetic glomerulosclerosis. Am J Physiol Renal Physiol 299: F99-F111, 2010.
39. Weigert C, Brodbeck K, Brosius FC, Huber M, Lehmann R, Friess U, Facchin S, Aulwurm S, Haring HU, Schleicher ED, Heilig CW. Evidence for a novel TGF-β1-independent mechanism of fibronectin production in mesangial cells overexpressing glucose transporters. Diabetes 52: 527-535, 2003.
40. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 124: 471-484, 2006.
41. Yang Y, Wang J, Qin L, Shou Z, Zhao J, Wang H, Chen Y, Chen J. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 27: 495-502, 2007.
42. Yeung RS, Xiao GH, Jin F, Lee WC, Testa JR, Knudson AG. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc Natl Acad Sci USA 91: 11413-11416, 1994.
43. Zhang H, Saha J, Byun J, Schin M, Lorenz M, Kennedy RT, Kretzler M, Feldman EL, Pennathur S, Brosius FC. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. Am J Physiol Renal Physiol 295: F1071-F1081, 2008.